M0324 + pembrolizumab

**M0324 + pembrolizumab** is a combination therapy currently under clinical investigation, primarily in oncology. M0324 appears to be a novel investigational agent, being evaluated both as a monotherapy and in combination with pembrolizumab (a PD-1 inhibitor) or chemotherapy. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting PD-1, widely approved for various cancers. The combination aims to enhance antitumor immune responses, leveraging pembrolizumab's immune checkpoint blockade and the (presumed) immunomodulatory activities of M0324. The precise mechanism of action and modality of M0324 is not defined in publicly available sources, but it may represent a novel immunotherapeutic or targeted agent based on its evaluation alongside immunotherapy and chemotherapy[3][4].